FDA DEVICE FACTS
Disposable Powder Free Nitrile Examination Glove, Blue Color, Tested For Use With Chemotherapy Drugs and Fentanyl Citrate
Ever Global (Vietnam) Enterprise Corp
FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。
Indications for use
A patient examination gloves is a disposable device intended for medical purpose that is worn on the examiner’s hand or fingers to prevent contamination between patient and examiner. In addition, these gloves were tested for use with chemotherapy drugs in accordance with ASTM D6978- 05 standard practice for assessment of resistance of medical gloves to permeation by chemotherapy drugs. Table 1 Tested for use with 55 chemotherapy drugs. No. Test Chemotherapy Drug and Concentration Minimum Breakthrough Detection Time (Min.) 1 Arsenic Trioxide (1.0 mg/ml) > 240 2 Azacitidine (Vidaza) (25.0 mg/ml) > 240 3 Bendamustine HCl (5.0 mg/ml) > 240 4 Bleomycin Sulfate (15.0 mg/ml) > 240 5 Bortezomib (Velcade) (1.0 mg/ml) > 240 6 Busulfan (6.0 mg/ml) > 240 7 Carboplatin (10.0 mg/ml) > 240 8 Carfilzomib (2.0 mg/ml) > 240 9 Carmustine (BCNU), (3.3 mg/ml) 6.2 10 Cetuximab (Erbitux) (2.0 mg/ml) > 240 11 Chloroquine (50.0 mg/ml) > 240 12 Cisplatin (1.0 mg/ml) > 240 13 Cladribine (1.0 mg/ml) > 240 14 Cyclophosphamide (20.0 mg/ml) > 240 15 Cyclosporine A (100.0 mg/ml) > 240 16 Cytarabine (100.0 mg/ml) > 240 17 Cytovene (Ganciclovir) (10.0 mg/ml) > 240 18 Dacarbazine (10.0 mg/ml) > 240 19 Daunorubicin (5.0 mg/ml) > 240 20 Decitabine (5.0 mg/ml) > 240 21 Docetaxel (10.0 mg/ml) > 240 22 Doxorubicin Hydrochloride (2.0 mg/ml) > 240 23 Epirubicin (Ellence) (2.0 mg/ml) > 240 24 Etoposide (20.0 mg/ml) > 240 25 Fludarabine (25.0 mg/ml) > 240 26 Fluorouracil (50.0 mg/ml) > 240 27 Fulvestrant (50.0 mg/ml) > 240 28 Gemcitabine (38.0 mg/ml) > 240 29 Idarubicin (1.0 mg/ml) > 240 30 Ifosfamide (50.0 mg/ml) > 240 31 Irinotecan (20.0 mg/ml) > 240 32 Mechlorethamine HCl (1.0 mg/ml) > 240 33 Melphalan (5.0 mg/ml) > 240 34 Methotrexate (25 mg/ml) > 240 35 Mesna (100 mg/ml) > 240 36 Mitomycin C (0.5 mg/ml) > 240 37 Mitoxantrone (2.0 mg/ml) > 240 38 Oxaliplatin (5.0 mg/ml) > 240 39 Paclitaxel (6.0mg/ml) > 240 40 Paraplatin (10.0 mg/ml) > 240 41 Pemetrexed (25.0 mg/ml) > 240 42 Pertuzumab (30.0 mg/ml) > 240 43 Raltitrexed (0.5 mg/ml) > 240 44 Retrovir (10.0 mg/ml) > 240 45 Rituximab (10.0 mg/ml) > 240 46 Temsirolimus (25.0 mg/ml) > 240 47 Thiotepa (10.0 mg/ml) 13.6 48 Topotecan HCl (1.0 mg/ml) > 240 49 Trastuzumab (21.0 mg/ml) > 240 50 Triclosan (2.0 mg/ml) > 240 51 Trisenox (1.0 mg/ml) > 240 52 Vinblastine (1.0 mg/ml) > 240 53 Vincristine Sulfate (1.0 mg/ml) > 240 54 Vinorelbine (10.0 mg/ml) > 240 55 Zoledronic Acid (0.8 mg/ml) > 240 Warning: do not use with Carmustine and Thiotepa. The maximum testing time is 240 minutes. Please note that the following drug has an extremely low permeation time: Carmustine (BCNU), 3.3 mg/ml 6.2 minutes Thiotepa, 10.0 mg/ml 13.6 minutes Fentanyl Permeation Resistance Claim - Under the testing conditions of ASTM D6978-05, Fentanyl Citrate Injection (100mcg/2mL) was found to have no breakthrough detected for up to 240 minutes.
Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。
OFFICIAL FDA SOURCES
FDA Record and Public Document Status
Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。